FULCRUM THERAPEUTICS, INC. Proceeds from (Repurchase of) Redeemable Preferred Stock
FULCRUM THERAPEUTICS, INC. (FULC) reported Proceeds from (Repurchase of) Redeemable Preferred Stock of $0 for the 12-month period ending 2021-12-31, per its 10-K/A filed 2023-06-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock · last filed 2023-06-26
- FULCRUM THERAPEUTICS, INC. proceeds from (repurchase of) redeemable preferred stock for fiscal 2021 was $0.00.
- FULCRUM THERAPEUTICS, INC. proceeds from (repurchase of) redeemable preferred stock for fiscal 2020 was -$193.00K.
| Period end | Proceeds from (Repurchase of) Redeemable Preferred Stock 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K/A · filed 2023-06-26 |
| 2020-12-31 | -$193.00K 10-K/A · filed 2023-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |